PBLS today
$28.11-$1.54 (-5.21%)close Nov 12, 2026Trend
DailyDowntrend (starting)
4 hourLeaning Bearish
1 hourStrong Bearish
15 minStrong Bearish
5 minStrong Bearish
Daily trend turns up above $42.48
Key levels
Resistance$33.76
Resistance$30.83
Support$27.11
Support$23.06
Latest news & SEC filings
EarningsParabilis Medicines Posts Q3 2026 Results, Business Update
SEC FilingParabilis Medicines, Inc. filed a report on a major company event (Form 8-K)
EarningsParabilis Medicines posts $0.36 per-share loss, revenue $2.114M tops $375K view
AnalystCanaccord Genuity starts Parabilis Medicines coverage with Buy rating and $39 price target
All PBLS news →Nasdaq · Healthcare
Parabilis Medicines, Inc. (PBLS)
What Is the Price Target for PBLS?
SEPT Low Target
$39.00
SEPT Mid Target
$40.00
SEPT High Target
$45.00
Analyst Consensus
$40.00
Is PBLS a Buy or Sell Right Now?
Thesis
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for PBLS.
Start Free Trial →Is PBLS Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
Analyst Consensus
Fair Value
$40.00
0
Moat Score
NONE
0/9
Piotroski Score
N/A
Altman Z-Score
What Is Smart Money Doing with PBLS?
Insider Signal
NEUTRAL
3 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | director 10% owner | Buy | 19,728,353 | $394.6M | Jun 11, 2026 |
| RA CAPITAL MANAGEMENT, L.P. | director 10% owner | Buy | 1,460,397 | $29.2M | Jun 11, 2026 |
| SEBULSKY ALAN | director | Buy | 12,500 | $250K | Jun 11, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →PBLS Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
N/A
FCF Growth YoY
N/A%
Revenue Trend
UNKNOWN
Dark Pool Trades for PBLS
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for PBLS, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 17:20:07 | $28.14 | 1,200 | $$34K | BUY |
| 17:19:59 | $28.22 | 1,600 | $$45K | SELL |
| 17:14:29 | $28.30 | 1,900 | $$54K | MIDPOINT |
| 17:14:29 | $28.30 | 5,100 | $$144K | SELL |
| 16:11:02 | $28.31 | 1,500 | $$42K | SELL |
5 dark pool trades shown · $$320K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Parabilis Medicines, Inc. (PBLS) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (2 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →PBLS — frequently asked questions
What is PBLS stock price today?
Parabilis Medicines, Inc. (PBLS) is at $28.11, down 5.21% (-$1.54) at the Nov 12, 2026 close.
Why is PBLS stock moving today?
Latest PBLS news — Nov 12, 2026: Parabilis Medicines Posts Q3 2026 Results, Business Update · Nov 12, 2026: Parabilis Medicines, Inc. filed a report on a major company event (Form 8-K)
Why did PBLS stock move on Oct 19, 2026?
Parabilis Medicines announced it will share new Zolucatetide results in desmoid tumor patients at the ESMO Congress 2026, with two separate headlines highlighting the upcoming clinical presentation. The stock rose sharply on the news, closing at $25.35, up 10.31% from the open of $22.98, while trading between a low of $22.98 and a high of $26.24 on volume of 2,088,069.
What is the PBLS price target?
The average analyst price target for PBLS is $40.00, ranging from $39 to $45, based on 4 analysts. Latest: Canaccord Genuity initiates on Nov 9, 2026.
What do analysts rate PBLS?
Analyst ratings for PBLS: 0 Buy, 4 Hold, 0 Sell — consensus Hold.
Did PBLS beat earnings?
PBLS last reported on Aug 13, 2026: EPS -$2.32 vs -$0.17 expected — a miss of 1306.1%.
What are PBLS support and resistance levels?
Support: $27.11, $23.06. Resistance: $30.83, $33.76, $38.00.
What are insiders doing with PBLS?
Insider activity: NEUTRAL, 3 buys and 0 sells in the last 90 days.
What is the latest news on PBLS?
Nov 12, 2026: Parabilis Medicines Posts Q3 2026 Results, Business Update · Nov 12, 2026: Parabilis Medicines, Inc. filed a report on a major company event (Form 8-K) · Nov 12, 2026: Parabilis Medicines posts $0.36 per-share loss, revenue $2.114M tops $375K view